文献速递脑血管病

不明来源栓塞性卒中:系统综述与临床更新

Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update.
PubMed 文献 · Stroke · 2017-03-06

该系统综述基于2014年以来的文献,评估不明来源栓塞性卒中(ESUS)的频率、患者特征与预后。ESUS占缺血性卒中的9%–25%,平均17%;患者平均年龄65岁,平均NIHSS评分5分,多数接受抗血小板治疗,年均复发卒中率4.5%。结论支持ESUS是常见卒中亚型,需优化抗栓预防策略。

要点

  • ESUS约占缺血性卒中的1/6,平均年龄65岁,多为轻型卒中。
  • 多数ESUS患者接受抗血小板治疗,年均复发卒中率约4.5%。
  • 现有研究多为回顾性,复发率证据有限,需更好抗栓预防方案。

核心结论

  • ESUS约占缺血性卒中的1/6,患者相对年轻且平均为轻型卒中,支持小栓塞机制。
  • 在多数接受抗血小板治疗的情况下,年均复发卒中率超过4%,需优化抗栓预防。

研究设计与样本

  • 系统文献综述,检索PubMed 2014年至今,不限语言,评估ESUS频率、患者特征与预后。

主要发现

  • 基于9项研究,ESUS占缺血性卒中的频率范围为9%–25%,平均17%。
  • 基于8项研究2045例ESUS患者,平均年龄65岁,42%为女性。
  • 基于4项研究1772例ESUS患者,卒中发生时平均NIHSS评分为5。
  • 基于5项研究1605例ESUS患者,平均随访2.7年,86%接受抗血小板治疗,年均复发卒中率平均4.5%。

临床怎么用

  • 对符合ESUS标准的缺血性卒中患者,应认识到其年均复发卒中风险超过4%。
  • 多数ESUS患者接受抗血小板治疗,但需进一步明确更优抗栓预防策略。

局限性

  • 现有研究多采用回顾性方法,限制了对卒中复发率估计的置信度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism. It has been hypothesized that anticoagulation is more efficacious than antiplatelet therapy for secondary stroke prevention in ESUS patients. We review available information about ESUS. METHODS: Systematic literature review to assess the frequency of ESUS, patient features, and prognosis using PubMed from 2014 to present, unrestricted by language. RESULTS: On the basis of 9 studies, the reported frequency of ESUS ranged from 9% to 25% of ischemic strokes, averaging 17%. From 8 studies involving 2045 ESUS patients, the mean age was 65 years and 42% were women; the mean NIH stroke score was 5 at stroke onset (4 studies, 1772 ESUS patients). Most (86%) ESUS patients were treated with antiplatelet therapy during follow-up, with the annualized recurrent stroke rate averaging 4.5% per year during a mean follow-up of 2.7 years (5 studies, 1605 ESUS patients). CONCLUSIONS: ESUS comprises about 1 ischemic stroke in 6. Patients with ischemic stroke meeting criteria for ESUS were relatively young compared with other ischemic stroke subtypes and had, on average, minor strokes, consistent with small emboli. Retrospective methods of available studies limit confidence in stroke recurrence rates but support a substantial (>4% per year) rate of stroke recurrence during (mostly) antiplatelet therapy. There is an important need to define better antithrombotic prophylaxis for this frequently occurring subtype of ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Hart RG, Catanese L, Perera KS, et al. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017. PMID: 28265016. doi:10.1161/STROKEAHA.116.016414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。